Search

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

With the Scientific Working Group for Stem Cells, the 18th Congress of EHA took the opportunity to acknowledge the work of the 2013 winner of the Nobel Prize for Medicine or Physiology, Drs John B.

Read more

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Read more

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

The EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy brought together basic science, as well as translational and clinical research on November 23-25, 2017 in Amsterdam, The Netherlands.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more

The HARMONY project: learning to work in BIG (DATA) teams

The HARMONY project: learning to work in BIG (DATA) teams

By Anna Kabanova PhD, YoungEHA committee member

On 26 and 27 September 2019 several YoungEHA members, including myself, had the chance to participate in the 4th General Assembly of the HARMONY Alliance…

Read more

COST Action ‘EuNet-INNOCHRON’

The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more